

BULLETIN

EDITED BY
MICHEL FOURNIER
DEPT. SC. BIOLOGIQUES
UQAM CP 8888
MONTREAL QUE
H3C 3P8

JANVIER 1987

VOL 18 (1)

ISSN: 0068-9653

CANADIAN SOCIETY FOR IMMUNOLOGY
SOCIETE CANADIENNE D'IMMUNOLOGIE

EDITOR'S MESSAGE

Congress

Canada acted as the host country of the 6th International Congress of Immunology in July 1986. There were more than 7,000 participants. The scientific sessions as well as the excellent social events have favored exchanges between scientifics of all over the world. All Canadian Immunologists should be proud of the Congress and we specially thank the organization committees.

The next congress of the CSI will take place at Lake Louise. At the moment, over 140 abstracts have been received by the organizing committee. As point out in the last general assembly in July 1986, the CSI has reach a critical point of its history regarding the annual meeting. It should be a duty to each canadian immunologists to attend this meeting in order to make it successfull.

Contents of the Bulletin

To the usual bulletin content, I will try to add articles on various immunology projects from laboratories not affiliated with universities, research centres or hospitals. The first article by Helen Tryphonas is on immunology and regulatory agencies.

The next issue of the bulletin should be in May. It will contain a number of new chronicles (opportunities, consumer reports for immunological products, etc.). If you have any idea to enhance the quality of the Bulletin do not hesitate to contact me. I would like to remind members to inform their regional correspondant to get news or informations published.

Acknowledgement

I would like to express appreciation of the membership to the past Editor for the Bulletin, Dr. P. Shek for his excellent service to the CSI members.

I would like to take also this opportunity to gratefully thank our past Secretary-Treasurer, Dr. H. Rode. By providing continuous valuable support and by playing a central role in managing a great numbers of functions, he served the CSI membership very well.

Regional Correspondents

Dr. John Bienenstock
Department of Pathology
Mc Master University
1200 Main Street West
Hamilton, Ontario
L8N 3Z5

Dr Michel Pagé
Département de Biochimie
Université Laval
Québec, Québec
G1K 7P4

Dr. R.M. Gorczynski
Ontario Cancer Institute
500 Sherbourne Street
Toronto, Ontario
M4X 1K9

Dr. Terry Pearson
Biochemistry Department
University of Victoria
Victoria, B.C.
V8W 2Y2

Dr. F.T. Kisil
Department of Immunology
University of Manitoba
Winnipeg, Manitoba
R3E 0W3

Dr. J.D. Reynolds
Dept. of Medical Physiology
The University of Calgary
Health Sciences Center
3330 Hospital Drive N.W.
Calgary, Alberta
T2N 4N1

Dr. M. Baines
Department of Microbiology
and Immunology
3775 University Street
Montreal, Quebec
H3A 2B4

Dr. Thomas G. Wegmann
Department of Immunology
8-45 Medical Sciences Building
University of Alberta
Edmonton, Alberta
T6G 2H7

Dr. R. Mazaheri
Transplant Immunology Lab.
University Hospital, Rm. BRE-25
339 Widemere Road
London, Ontario
N6A 5A5

Dr. B.N. Wilkie
Department of Veterinary
Microbiology & Immunology
University of Guelph
Guelph, Ontario
N1G 2W1

Dr. Mario Nemirovsky
Department of Anatomy
Centre Hospitalier Universitaire
Université de Sherbrooke
Sherbrooke, Quebec
J1H 5N4

There is no regional correspondent in Maritime. Is there any volunteer?

IMMUNOTOXICITY STUDIES AND SAFETY EVALUATION OF CHEMICALS

Helen Tryphonas

Regulatory Agencies whose main function is to establish a "safe" level for chemicals and drugs, are becoming increasingly conscious of the limitations inherent to presently employed methods for evaluation of chemically-induced immunotoxicity. For example, it was realized that limiting the examination of the immune system to total leukocyte counts and routine histopathology of the lymphoid organs, yields only very little information on which to base an evaluation of the potential immunotoxic effects of chemicals since it has been shown that subtle effects undetected by such means may compromise the function of the immune system leading to increased susceptibility to infection.

Accumulating evidence that chemically-induced immunosuppression is associated with an increased susceptibility to infection and cancer (reviewed by Vos, 1977; Dean et al, 1985; and Lewis et al, 1982) and the recent withdrawal of the nonsteroidal antiinflammatory drug Zomax from the market because of its adverse immune-mediated reactions lead to the decision to search for more appropriate methods of testing chemicals for immunotoxicity.

Among those who spearheaded such efforts are J.H. Dean, of the National Toxicology Program, J.G. Vos, of the Dutch National Institute of Health and L.D. Koller, of the University of Idaho. These investigators developed, and currently are in the process of validating, several pertinent immunologic tests using the mouse and the rat as animal models. They have also initiated interlaboratory studies with the objective of addressing significant issues concerning the reproducibility of these assays and their value in predicting potential hazard to the human.

A similar activity was recently initiated by H. Tryphonas of the Toxicology Research Division, Bureau of Chemical Safety, Food Directorate, Health Protection Branch. The objective of the Canadian program is to select from the available pool of immune assays the most appropriate and definitive immunologic tests by which to screen chemicals for immunotoxic effects and hopefully to define their mode of action. The ultimate application of results of the Canadian studies would be in the assessment of risk to humans associated with exposure to a potentially immunotoxic chemical. Ideally, the applied tests and the animal model used in immunotoxicity assessment should be relevant to the human. However, practical considerations of cost, reproducibility, time required for completion, and application to a routine toxicity study cannot be totally ignored.

In this respect, anatomo-physiologic similarities between the human and the rhesus monkey have prompted us to develop and validate a selected number of immune assays in the rhesus monkey and to investigate their suitability for chemical and drug immunotoxicity testing. Among the tests that have been explored to date are delayed hypersensitivity reactions following intentional sensitization with DNCB; lymphocyte blastogenic response to stimulation with the mitogens phytohemagglutinin (PHA) and concanavalin-A (Con-A), and with allogeneic lymphocytes (one-way mixed lymphocyte culture); antibody production to T-dependent and B-dependent (T-independent) antigens; lymphokine production by peripheral blood monocytes (IL1) and lymphocytes (IL2); and quantitative analysis of lymphocytes based on surface receptors and markers. The large number of tests presently used to evaluate chemical immunotoxicity reflects the current level of the state-of-the-art of immunotoxicology. This undoubtedly, will be simplified when results of ongoing interlaboratory validation studies become available.

Results of a number of these functional and quantitative immune assays used to test for immunotoxicity of polychlorinated biphenyls (PCBs) in the rhesus monkey were indicative of impairment of the immune competence and correlated well with those obtained by clinical immunologists in human. For example, adult female rhesus monkeys administered low levels of PCB (Aroclor 1254) in an ongoing PCB study show an impairment in their ability to produce antibodies to an immunizing dose of a T-lymphocyte dependent antigen compared to the results obtained in the control. Also, shifts in the T-helper/T-suppressor ratio and results of the lymphocyte transformation tests are similar to results obtained when the same tests were applied to humans exposed to PCBs through the ingestion of PCB-contaminated rice (Tryphonas et al, 1986). Application of these tests to the study of the effects of aroclor 1254 on the immune system of the in-utero exposed infants of the rhesus monkeys is a challenging prospect for the near future.

It is of interest to note that, while method validation is still investigated in the various laboratories, regulatory agencies including the European Economic Community, and the U.S. Bureau of Foods either have or are in the process of drafting regulations requiring that immunotoxicity testing be part of the toxicologic evaluation of chemicals and drugs.

In summary, the increasing number of chemicals and drugs that produce immunotoxic effects in humans and laboratory animals compels the adoption of a more comprehensive immunotoxicity program than that presently used in toxicity studies. Current progress in method development is encouraging. The demonstration of their feasibility and value in predicting immunologic risk to humans is challenging and promises to be a worthwhile undertaking.

REFERENCES

- Vos, J.G. (1977). Immune suppression as related to toxicology, CRC Crit. Rev. Toxicol. 5: 67-101.
- Dean, J.H., Luster, M.I., Munson, A.E., and Amos, H. (eds.) (1985). IMMUNOTOXICOLOGY AND IMMUNOPHARMACOLOGY, Raven Press, New York.
- Lewis, A.J., Carlson, R.P., and Chang, J. (1982). Therapeutic modulation of cellular mediated immunity. Ann Rep. Med. Chem. 17: 191-202.
- Tryphonas, H., D.L. Arnold, L. O'Grady, F. Bryce, S. Hayward and Z.Z. Zawidzka. (1986). Immunotoxicity studies of PCB (Aroclor 1254) in the adult rhesus (Macaca mulatta) monkey. Abstract. 6th International Congress of Immunology, Toronto, Can.

G.6.1: Minutes of the previous Annual General Meeting.

Dr. Bienenstock requested approval of the minutes of the Fifth Annual General Meeting held 20 June, 1985 at the University of Toronto, after first soliciting amendments and/or corrections.

G.6.1.1: Resolution That the minutes be accepted as previously circulated. This was moved by Dr. M. Fournier and seconded by Dr. E. Potworowski and carried by the members without dissent.

NEW BUSINESS

G.6.2. Dr. Bienenstock announced with regret that Dr. H. Rode had asked to step down as Secretary-Treasurer of the Society. Dr. Bienenstock expressed thanks to Dr. Rode for the way in which he had carried out his duties for the Society. This thanks was warmly endorsed by the membership. Dr. Bienenstock then announced that Dr. Ottaway had been elected by the Council to the office of Secretary-Treasurer to replace Dr. Rode.

G.6.3. Dr. Rode presented the 1984-85 Audited Financial Statements which had been published with the previous issue of the BULLETIN.

G.6.3.1: Resolution It was moved by Dr. Rode and seconded by Dr. Befus that these Statements be accepted. This motion was carried by the membership without dissent.

G.6.4. Dr. Rode presented an INTERIM Financial Statement regarding the Society's finances. Copies of this were circulated at the meeting and are appended to these minutes (Appendix 1). The key features of the statement were that the Society had a small net balance for the year ending 31 May, 1985, that the fees for members would remain unchanged for 1987, and that the detailed reports were still with the Auditors. Further information was presented by Dr. Rode regarding the funds from donations for the Sixth International Congress that were being held by the Society on behalf of the Society and the NRC. It was noted that these were being held in interest bearing accounts and certificates.

In response to a question from Dr. R. Phillips regarding the disposition of the interest accrued by these funds, Dr. Bienenstock explained that, in keeping with the existing agreements pertaining to the planning for the Congress, the funds were held on behalf of the Congress and that the proceeds would be forwarded to the Congress Organization subsequent to the Congress. The Society will not keep the interest directly, but the interest will be included in the accounts of the Congress, and the Society will benefit from any remaining funds of the Congress in the previously agreed form.

G6.4.1: Resolution: It was moved by Dr. Rode and seconded by Dr. Potworowski that the Interim Financial statements be accepted. This was carried by the membership without dissent.

G6.5 A number of membership changes were reported by Dr. Rode. There were 11 new full members and 7 new student members enrolled since the last meeting. One new corporate membership had also been enrolled. There were 5 resignations and 6 members were reported who had not paid their dues to the Society for at least three years. These latter members had been informed by registered letter of the Society's by-laws regarding dues payments.

G6.5.1 Resolution It was moved by Dr. Rode and seconded by Dr. Froese that the membership changes be officially recorded, and that those 6 members with dues outstanding for 3 or more years be struck from the roll of the Society unless they paid their dues by 1 September, 1986. The motion was carried by the membership without dissent.

G.6.6 Dr. Bienenstock announced that a subcommittee directed to fostering increased membership in the Society had been struck under the chairmanship of Dr. E. Potworowski. Dr. Potworowski reported that two issues were under study. First, he was beginning to identify key senior members of the Society in various centers who would be willing to approach appropriate scientists who were not at present members of the Society. Second, the subcommittee consisting of Dr. Potworowski, Dr. Lapp, Dr. Fornier and Dr. Ottaway were being asked to examine the issue of Student Membership and clarifying the role of students in the Society. Dr. Potworowski expressed the view that we should encourage students to be members and find ways of expanding their participation. In response to a question from the floor, he stated further that it might be possible to prepare information regarding the Society that would be distributed to Graduate Students across the Country. He further stated that he and the subcommittee would try to develop a variety of strategies that would be brought forward to the membership at the next meeting.

G.6.7 President's Report

Dr. Bienenstock emphasized two current issues: 1) Science Policy, and 2) the planning of the CSI meeting in March, 1987. With respect to Science Policy development, Dr. Bienenstock noted that the CFBS has become much more active and effective in this regard through the development of the office in Ottawa under the direction of Dr. C. Gautier. It was the perception of the President and of many members that Dr. Gautier was doing a good job and had substantially raised the profile of science in Canada. Dr. Bienenstock then emphasized that CSI is a member of CFBS, and that the CSI has a direct role in these efforts, and that Dr. D. Befus is the Society's representative to the Science Policy office.

Dr. Befus was asked to elaborate and reported that the key points regarding this mechanism were that:

- 1) Documentation from the scientific community now has a direct route to the Standing Committee of the House of Commons regarding Science Policy.
- 2) Organization has been developed for a National Lobbying Week each February. This is to be an annual exercise and CSI members should avail themselves of the opportunity that this provides.
- 3) Direct CFBS-to-MRC liason now exists.
- 4) Major issues, other than funding, that have been identified include animal rights, biotechnology, and the status of patent law protection.

A variety of discussion ensued. It was suggested that Dr. Bienenstock write to Dr. Gautier on behalf of the Society to express their thanks and support of the efforts mounted in the Ottawa Office. Dr. Bienenstock enthusiastically agreed to do so. A copy of Dr. Befus' report on Science Policy is appended to these minutes (Appendix 2). In response to a question from the floor regarding the status of the proposed MRC private sector matching program, Dr. Bienenstock said that it was clear that the Government was resolved to carry through this plan, but exact definitions of the way monies would be available, and the ways in which the "match" would be made were still unclear.

Dr. Bienenstock then directed attention to the plans being developed for the next CSI meeting to be held March 6-9, 1987, in Lake Louise, Alberta. The principal purpose of this meeting is to provide an opportunity to bring Canadian Immunologists together for good science in conjunction with good sociability at a reasonable cost. Dr. D. Befus of Calgary is acting as the local organizer for the meeting. Dr. Befus outlined the planned format of the

meeting and the preliminary arrangements that have been made with the Chateau Lake Louise. The principal features are that registration will be \$100.00 for members and \$50.00 for students, and that plans were being developed for a competition for some travel support for students who would be presenting at the meeting.

Discussion ensued regarding the nature and amounts of the proposed travel bursaries, and the way in which this should be awarded. It was the consensus of the meeting that the aim of the awards was to provide recognition to young scientists, and to encourage as much student involvement in the program as possible. Dr. Bienenstock and Dr. Befus welcomed the suggestions of the membership and stated that these would be taken into consideration in designing the exact methods to be used.

Dr. Bienenstock then reported on IUIS activities that were occurring at the Congress. He reported that Dr. B. Wilkie of Guelph had been elected as Chairman of the section for Veterinary Immunology. Dr. Bienenstock also announced the new executive of the IUIS consisting of President Nossal (Australia), Vice-President Natvig (Norway), Secretary Metzger (USA) and Treasurer Naismith (UK). Dr. H. Cinader had been nominated as a Councillor on behalf of the CSI. The next International Congresses of Immunology will be in Berlin (1989) and in Budapest (1992).

Dr. Bienenstock acknowledged the important contribution of many of the members to the Sixth International Congress. He expressed the view that the efforts of these members, and in particular those of Drs. Cinader, Dubiski, Froese, Hay, Letarte, Miller, Phillips and Sehon, had contributed greatly to the success of the current International Congress. This acknowledgement was warmly applauded by the membership.

Dr. Bienenstock then announced a change in the editorship of the CSI Bulletin. Dr. P. Shek had submitted his resignation as editor because of other commitments, and Dr. M. Fournier had agreed to take on this important role. Dr. Bienenstock thanked Dr. Shek for his past efforts for the Society in this role and thanked Dr. Fournier for assuming this duty for the Society. In future, information for the Bulletin should be directed to Dr. Fournier in Montreal.

There being no further business, the meeting was adjourned. The next Annual General Meeting of the CSI is to be held in conjunction with the scientific meeting in Lake Louise in March, 1987.

Respectfully submitted,

C. A. Ottaway,
Secretary to the CSI.

APPENDIX 1

THE CANADIAN SOCIETY FOR IMMUNOLOGY

Interim Financial statement for the

Year Ended May 31, 1985

ASSETS - May 31, 1984

Cash on Hand	
TSA	\$ 8,478.93
CA	38.66
Advance on CSI Symposium	<u>1,000.00</u>
	\$ 9,517.59

REVENUES

Membership Dues	18,333.70
Interest	494.99
Bulletin	900.00
CSI Symposia (CFBS)	3,000.00
Journal (Annual Reviews)	2,100.79
Other	377.04
CSI Social Event 1985	<u>1,058.12</u>
	\$ 26,264.64

EXPENSES

Levies	
CFBS	9,987.00
IUIS	722.11
Youth Science Foundation Membership	75.00
Perey Memorial Award	108.00
Canadians for Health Research Membership	100.00
Meetings	
6th International Congress	5,000.00
CSI Symposium 1984 - expenses	4,654.41
International Symposium London	1,000.00
Journal Expenses	1,933.06
Bank Charges	243.92
Auditor Fees	570.00
Legal Fees	61.00
Office and Postage	1,310.06
Typing	600.00
Printing and Copying	600.26
Bulletin	358.07
Other	<u>22.60</u>
	\$ 27,345.49
Bank charges for May	<u>73.22</u>
	\$ 27,418.71

ASSETS - May 31, 1985

Assets as of May 31, 1984	\$ 9,517.59
---------------------------	-------------

Deficit on year 1984-85	\$ 1,154.07	
Advance for Toronto Meeting	<u>2,000.00</u>	
	\$ 3,154.07	<u>3,154.07</u>

Cash on Hand as of May 31, 1985

- TSA & CA		\$ 6,363.52
Congress Account		332.54
TOTAL		<u>\$ 6,696.06</u>
Donations to Congress	\$79,861.00	
Interest	400.00	
	<u>\$80,261.54</u>	
Term Deposits	79,929.00	
Congress Account	<u>\$ 332.54</u>	

REVENUE

Membership fees	\$ 17,436.15
Interest	413.48
Bulletin	675.00
Symposia - Connaught	1,500.00
- CFBS	2,500.00
- CBS	1,629.24
CSI Social	1,588.38
Journal Revenue	3,126.39
Other	125.00
	<u>\$ 28,993.64</u>

EXPENSES

Levies	
CFBS	
CFBS - computer levy	\$ 7,925.00
IUIS	300.00
	669.92
Membership - CHR	
Perey Memorial Award	100.00
Meetings	108.00
CSI Symposia - 1985-86	
CSI Social	7,169.59
CSI Planning for 1987	1,928.55
CHR Workshop	724.99
Journal charges	75.00
Professional fees	2,779.09
Auditor	
Legal	675.00
Bank charges	228.15
Office	94.27
Telephone	
Postage	663.30
Other	592.80
Printing	31.58
Typing - Secretary	532.25
Resort Graphics - T-shirts	934.65
Bulletin	7,500.00
	<u>1,470.30</u>
TOTAL	\$ 34,502.44

Balance beginning of year	\$ 6,363.52
Deficit (Excess Expenses over Revenue)	<u>5,508.80</u>
Balance End of Year	\$ 854.72

Cash on Hand

TSA	\$837.40
CA	<u>17.32</u>
	\$854.72

SCIENCE POLICY COMMITTEE OF THE CANADIAN FEDERATION OF BIOLOGICAL SOCIETIES: A REPORT Dean Befus The University of Calgary

Overall, I believe that the Science Policy Committee (SPC) has had an active and productive year. Dr. Clement Gauthier, the Science Policy Officer was also appointed President, National Consortium of Scientific and Educational Societies which represents > 50,000 scientists and teachers across the country. These joint positions together with a central office in Ottawa have helped establish closer contact with governmental and non-governmental agencies.

I am pleased to report that as a result of the combined efforts of the CFBS, the National Consortium and many other bodies, the Standing Committee of the House of Parliament on Research, Science and Technology has been established. At one of the early meetings of this Committee, Drs. Gauthier, Bellaire and Lyassini of the National Consortium made official presentations concerning government research and development policies, the Canadian University System, and education and research training of international students in Canada. Minutes of this meeting and of other meetings of the Standing Committee are available from the House of Commons.

The SPC held a workshop at the CFBS meeting in Guelph in June. At this workshop issues relating to animals in research, the Patent Act, research funding and specifically the Matching Program, as well as the mandate of the SPC were discussed. The SPC recognizes and strongly encourages activities by groups such as "Canadians for Health Research" in their efforts to inform the public about the importance of animals in research and attempts to complement, but not replace, animals by new and innovative methodologies.

The CFBS has for many years called for amendments to the Patent Act that would promote more research by the pharmaceutical industry in Canada. The amendments to the Patent Act which were announced June 27, 1986 have been reviewed by members of the SPC and CFBS and major reservations have been expressed to the Hon. Harvey Andre, Minister of Consumers and Corporate Affairs. These relate to the definition of research and basically urge the government to link patent protection to Canadian research investment by the pharmaceutical companies. Further details of this are available from myself and Dr. Gauthier.

Report From the Montreal Chapter of CSI


Immunological research into both clinical and basic topics remains a strong feature of the Montreal biomedical scene. Within the last year at least 60 full length articles were published in the major journals by CSI members within the various university and hospital research units. Transplantation and surgical immunology remain strong points of interest. Drs. N. Christou and J. Meakins, Royal Victoria Hospital (RVH) have published at least 7 major papers on surgical sepsis and the role of malnutrition and immunological factors in risk assessment. Lymphocytes from anergic patients have been shown to react normally when provided with exogenous growth factors (Drs. H. Rode, McGill University (McU) and J. Gordon (McU)). Both McGill (McU) and University of Montreal (UoM) teaching hospitals are actively engaged in transplantation research and in particular, bone marrow transplants are being investigated by the groups of Drs. S. Cousineau (UoM), A. Fauser (RVH), R. Daniel (RVH), and M. Bernstein, (Montreal Childrens Hospital (MCH)). The immunology of rheumatic diseases is being studied by Drs. J. Rauch, (Montreal General Hospital (MGH)), H. Tannenbaum (MGH), J. Wall (MGH), R. Poole (Shriners Hospital (SH)) and P. Howson (SH). Drs. A. Brox (RVH) and D. Thompson (MGH) are performing both quantitative and qualitative assays of tumor specific antigens while Dr. A. Fuks (McU) is continuing his studies on the epitopes of CEA. The group of Drs. W. Lapp (McU), T. Seemayer (MCH) and M. Seddik (McU) have continued to elucidate the immunopathology and immune deficiency which accompanies graft versus host disease while Drs. R. Guttman (RVH), E. Colle (MCH) and G. Prud'homme (McU) have made significant progress in their studies of diabetes in the BB rat. Several groups are interested in resistance to experimental infectious diseases and their genetic control, including Drs. P. Kongshavn (McU), A. Sullivan (McU), E. Skamene (MGH), M. Wainberg (Jewish General Hospital (JGH)) and P. Viens (UoM). Macrophage mediated resistance to disease remains a strong area of interest (Dr. M. Stevenson (MGH)). Studies on the ontogeny of B cell dependent function (Dr. D. Osmond (McU)) and the thymus and T cell development (Drs. G. Sainte-Marie (UoM)) and (M. Pelletier (UoM)) continue to be very productive. Several groups are focusing upon the factors which augment or regulate immune recognition including Drs. S. Brandwein (MGH), W. Powell (RVH), R. Murgita (McU) and J. Menezes (UoM). Finally, the relationship of NK cells to the progression of malignant disease and the nature of NK specificity continues to attract considerable interest (Drs. B. Brenner (JGH), R. Margolese (JGH) and M. Baines (McU)). Dr. N. Gilmore (RVH) says that AIDS and retrovirology research will be strongly funded this year.

Of interest to those seeking career opportunities, almost all institutions have openings for both postdoctoral research associates and tenure track academic or research staff in the fields of immunology and microbiology. In particular, Dr. J. M. Dupuy has resigned as chairman of the Immunology Division of the Institut Armand Frappier to return to Lyons, France. On the other hand, Dr. E. Potworowski is ably taking over as acting chairman though he will not be doing much skiing at our March CSI meeting as he has broken his leg in 4 places.

Though I had but two weeks to survey the various centers for this newsletter, I hope to do better for the next newsletter if our Montreal and area members will send me any and all material over the next few months. If I missed you this time make sure your information reaches me before the next newsletter. Science, medicine, personnel opportunities and outright gossip gratefully accepted.

Malcolm Baines
Department of Microbiology and Immunology
3775 University Street
Montreal, Quebec H3A 2B4

obtained from the 1985 edition of the CSI Bulletin or from the Annual Report of the Immunological Sciences Research Group. This document can be obtained on request from the Group's Chairman, Dr Dean Befus, Department of Microbiology and Infectious Diseases, University of Calgary, 3330 Hospital Drive NW, Calgary, Alta, T2N 4N1.



M.S.

CINADER LECTURESHIP SPONSORED BY CONNAUGHT RESEARCH INSTITUTE

At the Spring Meeting of the Canadian Society for Immunology, March 6 - 9, 1987, in Chateau Lake Louise, the first "Cinader Lectureship sponsored by Connaught Research Institute" will be held. The first recipient of this award will be Dr. Bernard Cinader.

Given that this "Lectureship" is proposed to be an annual award of the CSI in recognition of the contributions of Dr. Cinader, we request that the membership of CSI make recommendations concerning the nature of the award and the topics for the associated lecture. The recommendations will be reviewed by a small sub-committee and clear guidelines established for the "Cinader Lectureship, sponsored by Connaught Research Institute".

Recommendations can be forwarded to Dr. Dean Befus, Dept. Microbiology & Infectious Diseases, The University of Calgary, Health Sciences Centre, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 4N1.

CANADIAN SOCIETY FOR IMMUNOLOGY
SPRING MEETING
LA SOCIÉTÉ CANADIENNE D'IMMUNOLOGIE
Chateau Lake Louise
March/Mars 6 - 9, 1987
Lake Louise, Alberta, Canada
Abstract and Registration deadline:
December 21, 1986
Correspondence to: Dr. Dean Befus
Dept. Microbiology & Infectious Diseases
The University of Calgary
Health Sciences Centre
Faculty of Medicine
3330 Hospital Drive N.W.
CALGARY, Alberta, T2N 4N1, Canada

POSTER INFORMATION

CSI Meeting, Lake Louise, Alberta, March 6 - 9, 1987.

Poster presentations for the Spring Meeting of the CSI will be in accordance with annual CFBS Guidelines. Thus the poster boards which will be available will be 4'x 6'.



Spicer MacGillivray

Chartered Accountants • Comptables Agréés

5075, RUE DE SOREL ST.
MONTREAL, QUEBEC H4P 1G6
TELEPHONE: (514) 731-7901

AUDITORS' REPORT

To the Member of
The Canadian Society for Immunology

We have examined the balance sheet of The Canadian Society for Immunology as at May 31, 1986 and the statement of receipts and disbursements for the year then ended. Our examination was made in accordance with generally accepted auditing standards, and accordingly included such tests and other procedures as we considered necessary in the circumstances.

In our opinion, these financial statements present fairly the financial position of the Society as at May 31, 1986 and the results of its operations for the year then ended, in accordance with generally accepted accounting principles, applied on a basis consistent with that of the preceding year.

SPICER MACGILLIVRAY
CHARTERED ACCOUNTANTS

Montreal, Quebec
September 11, 1986

THE CANADIAN SOCIETY FOR IMMUNOLOGY
STATEMENT OF RECEIPTS AND DISBURSEMENTS

	YEAR ENDED MAY 30	
	<u>1986</u>	<u>1985</u>
REVENUES		
Membership fees- including levies to the Canadian Federation of Biological Sciences and International Union of Immunological Sciences	\$ 17,436	\$ 18,334
Interest	8,802	895
Bulletin	725	900
CSI Symposia (CFSB)	-	3,000
Journal	3,126	2,101
CSI Social Event	7,293	1,058
Sponsorships and donations received re: the 6th International Congress	190,955	79,861
Other	-	377
	<u>228,337</u>	<u>106,526</u>
EXPENSES		
Levies		
Canadian Federation of Biological Sciences	8,225	9,987
International Union of Immunological Societies	670	722
Meetings		
CSI Symposia	9,898	4,654
International Symposium London	-	1,000
Funds advanced to the National Research Council re: the 6th International Congress	11,100	5,000
Promotion of 6th International Congress	7,500	-
Printing and copying	532	600
Office and postage	1,288	1,310
Dinner	2,779	1,933
Typing	935	600
Professional fees	903	631
Youth Science Foundation - Membership	-	75
- Perey Award	108	108
Canadians for Health Research - Membership	100	100
Bulletin and other	1,470	380
Bank charges	98	317
	<u>45,606</u>	<u>27,417</u>
EXCESS OF REVENUES OVER EXPENSES FOR THE YEAR	<u>\$ 182,731</u>	<u>\$ 79,109</u>

Spicer MacGillivray

Chartered Accountants • Comptables Agréés

THE CANADIAN SOCIETY FOR IMMUNOLOGY

SUPPLEMENTARY INFORMATION

STATEMENT OF AMOUNTS ACCUMULATED FOR THE 6TH INTERNATIONAL CONGRESS

	MAY 31	
	<u>1986</u>	<u>1985</u>
Total accumulation as at May 31, 1985 (including disbursements)	\$ 80,261	\$ -
Add: amounts accumulated during the current fiscal year	190,955	79,861
Income earned in year in respect of total accumulated property	<u>8,502</u>	<u>400</u>
Total accumulation to-date	279,718	80,261
Less: disbursements made to-date for the purpose of accumulation	<u>23,500</u>	<u>-</u>
Balance to be disbursed in approval period	<u>\$ 256,218</u>	<u>\$ 80,261</u>

Spicer MacGillivray

Chartered Accountants • Comptables Agréés

BIO/CAN SCIENTIFIC INC.

RESEARCH AND DIAGNOSTIC REAGENTS
RÉACTIFS DE RECHERCHE ET DE DIAGNOSTIQUE

* * * * * N E W S R E L E A S E * * * * *

BIO/CAN Affini Chart

LOCATE ANTIBODIES QUICKLY On Handy Wall Chart

If you have ever faced the daunting task of locating the affinity purified antibody you require from amongst the thousands of specificities and formats available, then the BIO/CAN Affini Chart will be a welcome addition to your laboratory. This attractive and functional wall chart lists more than 1,600 affinity purified antibodies in a convenient, easy to read arrangement.

The antibodies, produced by Jackson ImmunoResearch and distributed in Canada by BIO/CAN SCIENTIFIC INC., are purified by immunoaffinity chromatography, thus providing the highest specific reactivity. A unique sequential elution process is used to recover antibodies of the highest avidity. All antibodies are available as whole antibodies or as $F(ab')_2$ fragments.

The antibodies are available unconjugated and conjugated to biotin, peroxidase, alkaline phosphatase, glucose oxidase, fluorescein, rhodamine, and Texas Red. The biotin conjugates, termed Biotin-SP, utilize a 13-atom spacer between the biotin molecule and the antibody, thus reducing steric hindrance and increasing sensitivity. A complete line of avidin and streptavidin conjugates are also available.

The peroxidase and alkaline phosphatase conjugates are characterized by their high titer, so that working dilutions of 1:5,000 are routinely achieved in ELISA applications. These antibodies, along with the glucose oxidase conjugates, are also ideal for immunoblotting and immunohistochemical applications.

The BIO/CAN Affini Chart is available on request at no charge. Simply call BIO/CAN toll free at 1-800-387-8125 to receive your copy.



APPLICATION FOR MEMBERSHIP

DEMANDE D'ADHÉSION

NAME OF APPLICANT

NOM DU CANDIDAT

POSITION

POSTE

INSTITUTION

MAILING ADDRESS

ADRESSE POSTALE

Telephone number

Numéro de téléphone

PROFESSIONAL QUALIFICATIONS
(Degrees)

FORMATION PROFESSIONNELLE
(Diplômes universitaires)

Special field(s) of interest

Sujet(s) d'intérêt particulier

Signature of Applicant
(Date)

Signature du candidat
(Date)

SPONSORS (2 members of the
Canadian Society for Immunology)

PARRAINS (2 membres de la
Société canadienne d'immunologie)

1. Name/ Nom

2. Name/Nom

Address/ Adresse

Address/ Adresse

Signature

Signature

INDICATE MEMBERSHIP CATEGORY
RECOMMENDED

INDIQUER LA CATÉGORIE
RECOMMANDÉE

1. Member ___ Membre

2. Associate member ___ Membre associé

3. Emeritus member ___ Membre émérite

4. Student member ___ Membre étudiant

Applicants should append a curriculum
vitae and a list of publications with
full titles.

Les candidats doivent joindre un
curriculum vitae et une liste des
publications incluant les titres.

Please complete this form, obtain
signatures of Sponsors, and return
with 11 copies, including appendices
to::

Veuillez compléter ce formulaire,
obtenir les signatures des parrains,
et le faire parvenir en 11 copies
(y compris les appendices) a:

CSI c/o, Dr. C.A. Ottaway, Room 6360,
Medical Sciences Building, University of Toronto,
1 King's College Circle,
Toronto, Ontario, Canada, M5S 1A8.

I wish to receive correspondence
in English ___

Je desire recevoir la correspondance
en francais ___